$STE (Steris Plc)

$STE {{ '2016-05-18T11:37:43+0000' | timeago}} • Announcement

$STE announced that its BoD has authorized a quarterly dividend of $0.25 per common share, payable June 29, 2016 to shareholders of record on June 8, 2016.

$JNJ {{ '2018-01-23T20:02:58+0000' | timeago}} • Webcast

$JNJ said that it has approx $16Bil in cash accumulated in foreign markets. The pharma giant added that it plans to immediately transfer $12Bil of this amount into the country, to fund its US operations and also pay debts.

$PG {{ '2018-01-23T13:59:12+0000' | timeago}} • Announcement

$PG lifted FY18 core EPS growth outlook to 5-8% from 5-7% versus FY17 core EPS of $3.92. This is to reflect the potential benefit from the Tax Act. GAAP EPS are expected to decrease 30-32% versus FY17 GAAP EPS of $5.59, which included the significant benefit from the Beauty Brands transaction that was completed in October 2016.

$PG {{ '2018-01-23T13:58:56+0000' | timeago}} • Announcement

$PG maintained its organic sales growth estimate of 2-3% for FY18. The company estimates all-in sales growth of about 3% for FY18, which includes a neutral to half-a-percentage-point benefit to sales growth from the combined impacts of acquisitions and divestitures and foreign exchange.

$PG {{ '2018-01-23T13:58:44+0000' | timeago}} • Announcement

$PG's net sales for 2Q18 rose 3% year-over-year. This includes a 1% positive impact from foreign exchange. Organic sales and volume both increased 2%. A 1% positive mix impact from the disproportionate growth of higher priced categories, Skin & Personal Care and Personal Health Care, was offset by a negative pricing impact of 1%.

$PG {{ '2018-01-23T13:58:27+0000' | timeago}} • Announcement

$PG reported a 68% drop in 2Q18 earnings due to the Beauty Brands divestiture gain in the base period and the latest quarter net income tax charge related to the recent U.S. Tax Cuts and Jobs Act. Net income fell to $2.5Bil or $0.93 per share from $7.88Bil or $2.88 per share last year. Net sales rose 3% to $17.4Bil. Core EPS increased 10% to $1.19.

$PG {{ '2018-01-23T13:50:51+0000' | timeago}} • Infographic

$PG Procter & Gamble Co. Earnings AlphaGraphic: Q2 2018 Highlights

$JNJ {{ '2018-01-23T13:43:35+0000' | timeago}} • Announcement

$JNJ expects sales of $80.6Bil to $81.4Bil in FY18, reflecting expected operational growth in the range of 3.5% to 4.5%. Adjusted EPS for this period is estimated to be $8.00 to $8.20.

$JNJ {{ '2018-01-23T13:40:35+0000' | timeago}} • Announcement

Pharma giant $JNJ swung to a loss of $10.7Bil, or $3.99 per share in 4Q17, driven by tax-related expenses of $13.6Bil. Excluding the one-time costs, net income grew 10% to $1.74 per share. Riding on double-digit growth in drug sales during the quarter, total revenue jumped 11.5% to $20.2Bil.

$JNJ {{ '2018-01-23T13:27:16+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q4 2017 Highlights

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$XRAY {{ '2018-01-17T20:31:22+0000' | timeago}} • Announcement

$XRAY's BoD has appointed Donald M. Casey Jr. as CEO and board member of the company, effective Feb. 12, 2018. Casey succeeds Mark A. Thierer, who served as Interim CEO since Sept. 28, 2017.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$KAMN {{ '2018-01-16T17:22:14+0000' | timeago}} • Announcement

$KAMN said its Aerospace segment received a contract modification in excess of $17MM for the procurement of Joint Programmable Fuzes. The award is an additional order under Option 13 of the JPF contract with the US Air Force. The modification increases the total value of Option 13 to more than $102MM, all of which was in backlog at Dec. 31, 2017.

$KAMN {{ '2018-01-10T19:21:07+0000' | timeago}} • Announcement

$KAMN announced that Rebecca F. Stath has been appointed to serve as Assistant Vice President, SEC Compliance and External Reporting, reporting to John J. Tedone, Vice President, Finance and Chief Accounting Officer.

$KAMN {{ '2018-01-10T19:16:01+0000' | timeago}} • Announcement

$KAMN announced that Amanda N. Balboni has been appointed to serve as Assistant Vice President, Internal Audit. Ms. Balboni has previously worked at Coburn Technologies, Stanley Black & Decker and PricewaterhouseCoopers.

$MSA {{ '2018-01-09T19:42:03+0000' | timeago}} • Announcement

$MSA BoD declared 1Q18 dividend of 35 cents per share on common stock. The dividend is payable March 10, 2018 to shareholders of record on February 14, 2018.

$PII {{ '2018-01-09T19:13:23+0000' | timeago}} • Announcement

$PII named Lucy Clark Dougherty as its SVP, General Counsel, Compliance Officer and Corporate Secretary, reporting to Chairman and CEO Scott Wine effective Jan. 29, 2018. Dougherty will also serve as president of the Polaris Foundation.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
JCI (Johnson Controls Inc.)
Thursday, November 9 2017 - 4:00pm
SRCL (Stericycle, Inc.)
Wednesday, November 8 2017 - 10:01pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
KAMN (Kaman Corporation)
Friday, October 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
MTRN (Materion Corporation)
Thursday, October 26 2017 - 1:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
AIT (Applied Industrial Technologies, Inc.)
Wednesday, October 25 2017 - 2:00pm
EW (Edwards Lifesciences Corp.)
Tuesday, October 24 2017 - 9:00pm

AlphaGraphics you may like